Study: Both empirical, theoretical approaches needed to create AIDS vaccine

The National Institute of Allergy and Infections Diseases (NIAID), under the National Institutes of Health, looked back at the history of efforts to develop a preventive HIV vaccine.

The two approaches to seek out a cure provide insights into the disease. The empirical approach championed human testing, while the theoretical approach pushed for more research into immune responses to natural infections to design the vaccine.

"Ultimately, the theoretical and empirical approaches will coalesce, converging upon the effective vaccine so critically needed to end HIV transmission worldwide,"The study's authors, NIAID Director Dr. Anthony Fauci and Dr. Hilary Marston, said.

HIV presents a number of issues in developing preventive measures, although one empirical trial has seen some success. The RV144 trial in Thailand showed a 31 percent reduction in infection among vaccine recipients; others look to build on the success of this trial.

Scientists following the theoretical approach hope to design a vaccine based off a minority of the HIV-infected population's immune-system abilities to target HIV strains. If the scientists succeed, a vaccine would allow for the uninfected to develop broadly neutralizing antibodies.

Organizations in this Story

National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.